TITLE

Evaluation of 131I-Anti-Angiotensin II Type 1 Receptor Monoclonal Antibody as a Reporter for Hepatocellular Carcinoma

AUTHOR(S)
Hao, Pan-Pan; Liu, Yan-Ping; Yang, Chang-Ya; Liang, Ting; Zhang, Chao; Song, Jing; Han, Jian-Kui; Hou, Gui-Hua
PUB. DATE
January 2014
SOURCE
PLoS ONE;Jan2014, Vol. 9 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Finding a specific agent is useful for early detection of tumor. Angiotensin II type 1 receptor (AT1R) was reported to be elevated in a variety of tumors and participate in tumor progression. The aim of our study was to evaluate whether 131I-anti-AT1R monoclonal antibody (mAb) is an efficient imaging reporter for the detection of hepatocellular carcinoma. Methodology/Principal Findings: AT1R mAb or isotype IgG was radioiodinated with 131I and the radiochemical purity and stability of the two imaging agents and the affinity of 131I-anti-AT1R mAb against AT1R were measured. 3.7 MBq 131I-anti-AT1R mAb or isotype 131I-IgG was intravenously injected to mice with hepatocellular carcinoma through tail vein, and then the whole-body autoradiography and biodistribution of the two imaging agents and the pharmacokinetics of 131I-anti-AT1R mAb were studied. 131I-anti-AT1R mAb and 131I-IgG were successfully radioiodinated and both maintained more stable in serum than in saline. The 131I-anti-AT1R mAb group showed much clearer whole-body images for observing hepatocellular carcinoma than the 131I-IgG group. The biodistributions of the two imaging agents suggested that hepatocellular carcinoma tissue uptook more 131I-anti-AT1R mAb than other tissues (%ID/g = 1.82±0.40 and T/NT ratio = 7.67±0.64 at 48 h), whereas hepatocellular carcinoma tissue did not selectively uptake 131I-IgG (%ID/g = 0.42±0.06 and T/NT ratio = 1.33±0.08 at 48 h). The pharmacokinetics of 131I-anti-AT1R mAb was in accordance with the two-compartment model, with a rapid distribution phase and a slow decline phase. These results were further verified by real-time RT-PCR, immunohistochemistry staining and Western blot. Conclusions/Significance: 131I-anti-AT1R mAb may be a potential target for early detection of tumor.
ACCESSION #
94234221

 

Related Articles

  • Loss of Cell-Cell Contact Is Induced by Integrin-Mediated Cell-Substratum Adhesion in Highly-Motile and Highly-Metastatic Hepatocellular Carcinoma Cells. Genda, Takuya; Sakamoto, Michiie; Ichida, Takafumi; Asakura, Hitoshi; Hirohashi, Setsuo // Laboratory Investigation (00236837);Mar2000, Vol. 80 Issue 3, p387 

    The cadherin-mediated cell-cell adhesion system plays a critical role in normal development and morphogenesis. Inactivation of this system is thought to be responsible for cancer invasion and metastasis. A human hepatocellular carcinoma (HCC) cell line, KYN-2, was observed to have great...

  • Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Yokoyama, H.; Ikehara, Y.; Kodera, Y.; Ikehara, S.; Yatabe, Y.; Mochizuki, Y.; Koike, M.; Fujiwara, M.; Nakao, A.; Tatematsu, M.; Nakanishi, H. // British Journal of Cancer;12/4/2006, Vol. 95 Issue 11, p1504 

    Gastric cancer metastasised to the liver was found to overexpress HER2 at a significantly higher incidence than primary gastric cancers. The purpose of the present study was to investigate the possibility of molecular therapy targeting HER2 overexpression in gastric cancer liver metastasis. We...

  • The important role of ADAM8 in the progression of hepatocellular carcinoma induced by diethylnitrosamine in mice. Li, S-Q; Wang, D-M; Zhu, S.; Ma, Z.; Li, R-F; Xu, Z-S; Han, H-M // Human & Experimental Toxicology;Nov2015, Vol. 34 Issue 11, p1053 

    This study focuses on investigating the concrete role of a disintegrin and metalloproteinase 8 (ADAM8) in the progression of hepatocellular carcinoma (HCC). Mice received anti-ADAM8 monoclonal antibody (mAb) of 100 μg/100 μl, 200 μg/100 μl or 300 μg/100 μl, respectively, in...

  • Edrecolomab (Monoclonal Antibody 17-1A): A Viewpoint by John Zalcberg. Zalcberg, J. // Drugs;Oct1998, Vol. 56 Issue 4, p627 

    Presents a viewpoint on the place of edrecolomab (Monoclonal Antibody 17-1A) in the treatment of metastatic tumors. Problem associated with tumor-specific antigens; Mechanism of action of the medication.

  • Multiple regression analysis for assessing the growth of small hepatocellular carcinoma: the MIB-1 labeling index is the most effective parameter. Saito, Yoshifumi; Matsuzaki, Yasushi; Doi, Mikio; Sugitani, Takehiko; Chiba, Toshiya; Abei, Masato; Shoda, Junichi; Tanaka, Naomi; Saito, Y; Matsuzaki, Y; Doi, M; Sugitani, T; Chiba, T; Abei, M; Shoda, J; Tanaka, N // Journal of Gastroenterology;1998, Vol. 33 Issue 2, p229 

    The aim of this study was to clarify whether histological parameters reflected tumor aggressiveness in patients with hepatocellular carcinoma (HCC). The tumor volume doubling times (TVDTs) of 21 HCCs, less than 3 cm in diameter at the start of the observation period, were calculated in 21...

  • MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer. Suzuki, S; Sasajima, K; Sato, Y; Watanabe, H; Matsutani, T; Iida, S; Hosone, M; Tsukui, T; Maeda, S; Shimizu, K; Tajiri, T // British Journal of Cancer;7/22/2008, Vol. 99 Issue 2, p350 

    Tumour samples from 71 patients with stomach cancer, 41 patients with liver metastasis (group A) and 15 patients each in stages II–IV (group B) and stage I (group C) without liver metastasis were analysed. MAGE-A protein expression was evaluated by immunohistochemistry using a 6C1...

  • Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues. Sandomenico, C.; Costanzo, R.; Carillio, G.; Piccirillo, M. C.; Montanino, A.; Di Maio, M.; Rocco, G.; Normanno, N.; Perrone, F.; Morabito, A. // Current Medicinal Chemistry;Mar2012, Vol. 19 Issue 7, p961 

    Bevacizumab is a monoclonal antibody directed against Vascular Endothelial Growth Factor (VEGF). Evidence about its efficacy in addition to first-line chemotherapy in non-small-cell-lung-cancer (NSCLC) has been produced by two large randomized phase III clinical trials (ECOG 4599 and AVAiL),...

  • Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Loureiro, Liliana R.; Carrascal, Mylène A.; Barbas, Ana; Ramalho, José S.; Novo, Carlos; Delannoy, Philippe; Videira, Paula A. // Biomolecules (2218-273X);2015, Vol. 5 Issue 3, p1783 

    The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with immunosuppressive microenvironment. Presently they are used in clinical...

  • Edrecolomab (Monoclonal Antibody 17-1A): A Viewpoint by Harry Bleiberg. Bleiberg, H. // Drugs;Oct1998, Vol. 56 Issue 4, p627 

    Presents a viewpoint on the use of edrecolomab (Monoclonal Antibody 17-1A) for the treatment of metastatic tumors. Categories of immunotherapy; Rationale for using monoclonal antibodies.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics